WS #10229
AbbVie reportedly acquiring Apogee and its Dupixent rival for nearly $11B, a significant biotech M&A signal.
AbbVie-Apogee Acquisition Rumor
AbbVie reportedly acquiring Apogee and its Dupixent rival for nearly $11B, a significant biotech M&A signal.